Postoperative assessment of malignant melanoma aggressiveness for further treatment personalization
https://doi.org/10.18027/2224-5057-2021-11-1-45-51
Abstract
The aim of the study was to develop, implement and evaluate a method for predicting the aggressiveness of primary melanoma after surgical removal.
It was established that the method for predicting tumor aggressiveness allows to determine the degree of aggressiveness, life expectancy, and to identify patients with poor prognosis in order to individualize treatment. The survival rate of patients was found to depend on the degree of aggressiveness of the tumor. A group of patients with stages 0-IIa (16,4 %) and tumor aggressiveness Grade II was identified as having a potentially high risk of progression, which can help individualize treatment for this category of patients. Using the method for predicting disease progression may potentially expand the scope of indications for further personalized treatment.
About the Authors
S. A. Yargunin
Clinical Oncological Center No. 1
Russian Federation
Competing Interests:
Russian Federation
Sergey A. Yargunin - MD, PhD, Head of the Department of Skin Tumor Surgery, Clinical Oncological Center No. 1.
Krasnodar.
Competing Interests:
No
Ya. N. Shoikhet
Altai State Medical University
Russian Federation
Competing Interests:
Russian Federation
Yakov N. Shoikhet - MD, PhD, DSc, Corr. Member of RAS, Head of the Department of Hospital Surgery, Altai State Medical University.
Barnaul.
Competing Interests:
No
A. F. Lazarev
Altai State Medical University
Russian Federation
Competing Interests:
Russian Federation
Aleksandr F. Lazarev - MD, PhD, DSc, Head of the Department of Oncology with a Course of Medical Imaging and Radiation Therapy, Altai State Medical University.
Barnaul.
Competing Interests:
No
References
1. Rockberg J., Amelio J. M., Taylor A. et al. Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence. Int J Cancer 2016; 139:2722-9.
2. Abdel - Rahman O. Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis. J Dermatolog Treat 2018; 29:176-81.
3. Korn E. L., Liu P. Y., Lee S. J. et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 1; 26 (4):527-34. doi: 10.1200/JCO.2007.12.7837. PMID: 18235113.
4. Balch C. M., Gershenwald J. E., Soong S. J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-206. 10.1200/JCO.2009.23.4799.
5. Doyle C. Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma. Am Health Drug Benefits. 2015; 8 (Spec Issue): 41 Epub 2015/09/19.
6. Chae Y. K., Arya A., Iams W., et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018; 6 (1):39 Epub 2018/05/18.10.1186/s40425-018-0349-3.
7. Albittar A. A., Alhalabi O., Glitza O. Immunotherapy for Melanoma. Adv Exp Med Biol. 2020; 1244:51-68. 10.1007/978-3-030-41008-7_3.
8. Riker A. I., Enkemann S. A., Fodstad O. et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008; 1 (1):1-16.
9. Mohammadpour A., Derakhshan M., Darabi H., et al. Melanoma: where we are and where we go. J Cell Physiol. 2019; 234 (4):3307-3320.
10. Abbas O., Miller D. D., Bhawan J. Cutaneous malignant melanoma. Am J Dermatopathol. 2014; 36 (5): 363-379.
11. Weiss S. A., Hanniford D., Hernando E., et al. Revisiting determinants of prognosis in cutaneous melanoma. Cancer-Am Cancer Soc 2015; 121:4108-23.
12. Enninga E., Moser J. C., Weaver A. L. et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States. Cancer Med 2017; 6:2203-12.
13. Cherobin A. C. F. P., Wainstein A. J. A., Colosimo E. A., et al. Prognostic factors for metastasis in cutaneous melanoma. An Bras Dermatol 2018; 93:19-26.
14. Yang J., Pan Z., Zhao F., et al. A nomogram for predicting survival in patients with nodular melanoma: A populationbased study. Medicine (Baltimore). 2019 Jun; 98 (24):e16059. doi: 10.1097/MD.0000000000016059. PMID: 31192966.
15. Cavanaugh - Hussey M. W., Mu E. W., Kang S. et al. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003-2011). Ann Surg Oncol 2015; 22:2120-6.
16. Gimotty P. A., Shore R., Lozon N. L. et al. Miscoding of melanoma thickness in SEER: research and clinical implications. J Invest Dermatol 2016; 136:2168-72.
17. Ciarrocchi A., Pietroletti R., Carlei F. et al. Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER). Colorectal Dis 2017; 19:158-64.
18. Jang B-S, Chang J. H., Oh S., et al. Surgery vs. radiotherapy in patients with uveal melanoma: analysis of the SEER database using propensity score matching and weighting. Strahlenther Onkol 2017; 193:931-42.
19. Pasquali S., Hadjinicolaou A. V., Chiarion Sileni V. et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018; 2: CD011123.
20. Hu Z., Rong Y., Li S., et al. Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients. Cancer Manag Res. 2020 Dec 17; 12:12993-13001. doi: 10.2147/CMAR.S284199. eCollection 2020. PMID: 33364845.
Review
For citations:
Yargunin S.A., Shoikhet Ya.N., Lazarev A.F. Postoperative assessment of malignant melanoma aggressiveness for further treatment personalization. Malignant tumours. 2021;11(2):45-51. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-1-45-51
Views:
375
Email this article 